
    
      -  To evaluate the repeat-dose pharmacokinetics (PK) of HM10660A when given by weekly,
           biweekly, and monthly subcutaneous (SC) injection.

        -  To evaluate the repeat-dose pharmacodynamics (PD) of HM10660A when given by weekly,
           biweekly, and monthly SC injection.

        -  To explore the antiviral activity of HM10660A at Week 4, Week 12, and Week 24.
    
  